Whitehawk Therapeutics Presents Two-Real World Analyses Supporting Mucin 16

 

MUC16 Expression Remained High and Stable Following Standard-of-Care Therapies, Supporting Its Potential Utility in Both Combination Approaches and Relapsed Settings

High MUC16 Expression Was Associated with Poor Real-World Overall Survival in High-Grade Serous Ovarian Carcinoma, the Most Common Subtype of Ovarian Cancer

Findings Reinforce the Scientific Rationale for HWK-016, Whitehawk's Next-Generation MUC16-Directed ADC Currently in Phase 1 Development